Windtree Therapeutics, Inc. (NASDAQ:WINT) Short Interest Up 353.8% in January

Windtree Therapeutics, Inc. (NASDAQ:WINTGet Free Report) was the target of a large increase in short interest during the month of January. As of January 31st, there was short interest totalling 229,600 shares, an increase of 353.8% from the January 15th total of 50,600 shares. Based on an average daily volume of 282,000 shares, the short-interest ratio is presently 0.8 days. Approximately 5.3% of the company’s stock are short sold.

Wall Street Analyst Weigh In

Separately, HC Wainwright reaffirmed a “neutral” rating on shares of Windtree Therapeutics in a research note on Wednesday, January 3rd.

Get Our Latest Report on Windtree Therapeutics

Windtree Therapeutics Stock Performance

Windtree Therapeutics stock traded down $0.01 on Monday, reaching $0.35. 16,895 shares of the stock were exchanged, compared to its average volume of 476,495. The company has a quick ratio of 2.40, a current ratio of 2.40 and a debt-to-equity ratio of 2.00. Windtree Therapeutics has a twelve month low of $0.34 and a twelve month high of $19.06. The firm has a fifty day moving average price of $0.62 and a two-hundred day moving average price of $0.95.

Windtree Therapeutics (NASDAQ:WINTGet Free Report) last released its earnings results on Thursday, November 9th. The company reported ($0.86) earnings per share for the quarter. As a group, analysts expect that Windtree Therapeutics will post -4.34 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Renaissance Technologies LLC increased its holdings in shares of Windtree Therapeutics by 54.1% during the 2nd quarter. Renaissance Technologies LLC now owns 361,395 shares of the company’s stock worth $151,000 after purchasing an additional 126,949 shares during the period. Envestnet Asset Management Inc. increased its holdings in shares of Windtree Therapeutics by 97.8% during the 4th quarter. Envestnet Asset Management Inc. now owns 212,236 shares of the company’s stock worth $36,000 after purchasing an additional 104,934 shares during the period. Millennium Management LLC increased its holdings in shares of Windtree Therapeutics by 411.1% during the 2nd quarter. Millennium Management LLC now owns 79,858 shares of the company’s stock worth $33,000 after purchasing an additional 64,232 shares during the period. Virtu Financial LLC bought a new position in shares of Windtree Therapeutics during the 2nd quarter worth about $54,000. Finally, Vanguard Group Inc. bought a new position in shares of Windtree Therapeutics during the 3rd quarter worth about $40,000. Institutional investors and hedge funds own 21.98% of the company’s stock.

Windtree Therapeutics Company Profile

(Get Free Report)

Windtree Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company's lead development programs include istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as in Phase 2a clinical trial for the treatment of early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant, which is in Phase 2b clinical trial to treat respiratory distress syndrome in premature infants; Surfaxin, a lyophilized KL4 surfactant, which is in Phase 2a clinical trial for the treatment of lung injury resulting from COVID-19; Rostafuroxin that is in Phase 2b clinical trial for the treatment of genetically associated hypertension; and oral and intravenous SERCA2a activator, which is in preclinical trial for the treatment of chronic and acute heart failure.

Further Reading

Receive News & Ratings for Windtree Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Windtree Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.